Ask AI
DLBCL Treatment Tool
Expert Guidance for the Treatment of DLBCL

Released: January 22, 2026

About This Tool and Disclaimer

Decera Clinical Education is grateful to John N. Allan, MD; Jeremy S. Abramson, MD, MMSc; Brad Kahl, MD; Krish Patel, MD; and Laurie H. Sehn, MD, MPH, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in January 2026 and reflects the evidence available at that time.

The goal of the tool is to educate healthcare professionals on making optimal treatment choices for patients with diffuse large B-cell lymphoma (DLBCL). A series of questions allow the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include DLBCL subtype, previous treatment, disease stage and International Prognostic Index (IPI) score, and the presence of bulky disease.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with DLBCL. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate for making management decisions.

Based on the characteristics entered, the tool will display expert recommendations for that specific patient case.

For additional information on best practices in the management of patients with DLBCL, follow the link for online modules and commentaries authored by Jeremy S. Abramson, MD, MMSc, and others.

This program is supported by an educational grant from AstraZeneca.

© 2026 - Clinical Education Alliance, LLC dba Decera Clinical. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Expert Guidance for the Treatment of DLBCL” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for patients with DLBCL. The information provided is based on guideline recommendations and the expert guidance of John N. Allan, MD; Jeremy S. Abramson, MD, MMSc; Brad Kahl, MD; Krish Patel, MD; and Laurie H. Sehn, MD, MPH.

The material published by Decera Clinical Education reflects the views of the reviewers or authors of this material, not those of Decera Clinical Education, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Expert Guidance for the Treatment of DLBCL” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2026 - Clinical Education Alliance, LLC dba Decera Clinical. All rights reserved.

Program Content